InvestorsHub Logo
Followers 71
Posts 2108
Boards Moderated 0
Alias Born 12/06/2013

Re: None

Tuesday, 10/30/2018 7:37:47 AM

Tuesday, October 30, 2018 7:37:47 AM

Post# of 3857
Deal



I like the way they structured the deal with a modest amount of restricted stock up front and the remainder vesting over three years. Smart move on Nexien's part.

Seems like a modest price to pay to acquire three patents and build out the team with more experience in CBD. Hopefully the market likes the new CEO. I am pleased that Alain will stay as Chairman to oversee things and remain Chief Strategy Officer. Everyone on the team should be motivated to boost the stock price so they can raise additional capital. I guess I understand now why they've been tight-lipped and had infrequent communications with investors.

Hopefully we'll get more news on the FDA pathway. Perhaps this acquisition was done to augment the team in anticipation of a ramp up of research activity.

Anyone else have thoughts?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NXEN News